| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | -7.5MM | -244% |
| Gross Profit | 5.6MM | - |
| Cost Of Revenue | -13.1MM | -253% |
| Operating Income | 35.7MM | -376% |
| Operating Expenses | -30.1MM | - |
| Net Income | -33.8MM | - |
| R&D | -14.2MM | -397% |
| G&A | -12.2MM | -264% |
| Amortization | -250K | -350% |
| Interest Expense | 1.5MM | +10% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Acutus Medical ( NASDAQ:AFIB ) Full Year 2023 Results Key Financial Results Revenue: US$7.16m (down 56% from FY 2022...
CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023. Recent Highlights: Announced strategic realignment of resources and corporate restructuring on November 8, 2023 with the objective of optimizing financial position and maximizing free cash flow.The Continuing Operations focuses on the implementation of the business model to shift to solely support
The company has decided to exit the mapping and ablation business and focus its remaining cash on the Medtronic partnership.
Improvements in Operating Efficiency and Strategic Partnerships Drive Performance
CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the third quarter of 2023. Recent Highlights: Third quarter revenue of $5.2 million grew 44% year-over-year, led by strong growth in distribution revenue from sales of left-heart access products to MedtronicRegistered significant year-over-year reductions in both GAAP and non-GAAP operating expenses and cash burn, resulting from disciplined focus on expen
CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced a realignment of resources and corporate restructuring. Scott Huennekens, Chairman of Acutus, commented, “Following an extensive strategic review by the Company’s Board of Directors, we are taking the hard but necessary steps to streamline our operations. In light of the current financing environment and the capital investments required to achieve leadership in the
CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent
CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on November 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 5 individuals hired by Acutus in October 2023. The equity aw
Acutus Medical, Inc. (NASDAQ:AFIB) Q2 2023 Earnings Call Transcript August 7, 2023 Acutus Medical, Inc. misses on earnings expectations. Reported EPS is $-0.63 EPS, expectations were $0.61. Operator: Good day, and thank you for standing by, and welcome to the Acutus Medical Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s […]
Q2 2023 Acutus Medical Inc Earnings Call